Literature DB >> 8240742

Cytokine dysregulation as a mechanism of graft versus host disease.

J L Ferrara1.   

Abstract

Graft versus host disease (GVHD) remains the major complication of allogeneic bone marrow transplantation. T cells in the donor bone marrow recognize and react against host alloantigens and thereby initiate GVHD, but the precise mechanisms by which host tissues are damaged remain unclear. Recently, several convergent lines of evidence have suggested that inflammatory cytokines act as mediators of acute GVHD. Most of the clinical manifestations of GVHD may in fact be due to the dysregulated production of cytokines by T cells and other inflammatory cells. The complex interactions among cytokines and their cellular targets suggest that individual cytokines may play an important and distinctive role in the pathophysiology of GVHD. Perturbation of the cytokine network may function as a final common pathway of target organ damage, and the rapid onset of severe, acute GVHD can be considered a 'cytokine storm.'

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8240742     DOI: 10.1016/0952-7915(93)90139-j

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  51 in total

1.  The new stem cell biology.

Authors:  Peter J Quesenberry; Gerald A Colvin; Jean-Francois Lambert; Angela E Frimberger; Mark S Dooner; Christina I Mcauliffe; Caroline Miller; Pamela Becker; Evangelis Badiavas; Vincent J Falanga; Gerald Elfenbein; Lawrence G Lum
Journal:  Trans Am Clin Climatol Assoc       Date:  2002

Review 2.  Into the eye of the cytokine storm.

Authors:  Jennifer R Tisoncik; Marcus J Korth; Cameron P Simmons; Jeremy Farrar; Thomas R Martin; Michael G Katze
Journal:  Microbiol Mol Biol Rev       Date:  2012-03       Impact factor: 11.056

3.  Perforin/granzyme-dependent and independent mechanisms are both important for the development of graft-versus-host disease after murine bone marrow transplantation.

Authors:  T A Graubert; J F DiPersio; J H Russell; T J Ley
Journal:  J Clin Invest       Date:  1997-08-15       Impact factor: 14.808

4.  Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus.

Authors:  Kevin B Walsh; John R Teijaro; Peter R Wilker; Anna Jatzek; Daniel M Fremgen; Subash C Das; Tokiko Watanabe; Masato Hatta; Kyoko Shinya; Marulasiddappa Suresh; Yoshihiro Kawaoka; Hugh Rosen; Michael B A Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2011-06-29       Impact factor: 11.205

5.  A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism.

Authors:  Eleonora Trotta; Paul H Bessette; Stephanie L Silveria; Lauren K Ely; Kevin M Jude; Duy T Le; Charles R Holst; Anthony Coyle; Marc Potempa; Lewis L Lanier; K Christopher Garcia; Natasha K Crellin; Isaac J Rondon; Jeffrey A Bluestone
Journal:  Nat Med       Date:  2018-06-25       Impact factor: 53.440

Review 6.  Multiple mechanisms of immune suppression by B lymphocytes.

Authors:  Matthew W Klinker; Steven K Lundy
Journal:  Mol Med       Date:  2012-02-10       Impact factor: 6.354

Review 7.  Context, tissue plasticity, and cancer: are tumor stem cells also regulated by the microenvironment?

Authors:  Mina J Bissell; Mark A Labarge
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

8.  Immunotransplantation preferentially expands T-effector cells over T-regulatory cells and cures large lymphoma tumors.

Authors:  Joshua D Brody; Matthew J Goldstein; Debra K Czerwinski; Ronald Levy
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

9.  Unique patterns of CD8+ T-cell-mediated organ damage in the Act-mOVA/OT-I model of acute graft-versus-host disease.

Authors:  Barbara Érsek; Nikolett Lupsa; Péter Pócza; Anett Tóth; Andor Horváth; Viktor Molnár; Bence Bagita; András Bencsik; Hargita Hegyesi; András Matolcsy; Edit I Buzás; Zoltán Pós
Journal:  Cell Mol Life Sci       Date:  2016-04-30       Impact factor: 9.261

10.  A preclinical acute GVHD mouse model based on chemotherapy conditioning and MHC-matched transplantation.

Authors:  K Riesner; M Kalupa; Y Shi; S Elezkurtaj; O Penack
Journal:  Bone Marrow Transplant       Date:  2015-11-23       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.